Journal of Physiology & Pathology in Korean Medicine (동의생리병리학회지)

The Physiological Society of Korean Medicine and The Society of Pathology in Korean Medicine (대한동의생리학회·한의병리학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of the Single Oral Combination Treatment of Tamoxifen with Gamisoyo-san on the Pharmacokinetics Profiles of Tamoxifen

  • Kim, Joo-Ik (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Ku, Sae-Kwang (Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University) ;
  • Lee, Young-Joon (Department of Preventive Medicine, College of Korean Medicine, Daegu Haany University)
  • Received : 2020.04.06
  • Accepted : 2020.08.10
  • Published : 2020.08.25
Download PDF
⟨ Previous Next ⟩

Abstract

The effects of Gamisoyo-san (GMSYS) co-administration within 5 min on the pharmacokinetics (PK) of tamoxifen were observed. After 50 mg/kg of tamoxifen oral treatment, GMSYS 100 mg/kg was orally administered within 5 min to 7-wk old male SPF.VAF Outbred Crl:CD [Sprague-Dawley (SD)] rats. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of GMSYS treatment, and plasma concentrations of tamoxifen were analyzed using LC-MS/MS methods. Tmax, Cmax, AUC, t1/2 and MRTinf of tamoxifen were analysis as compared with tamoxifen single administered rats. Although co-administration with GMSYS did not critically influenced on the pharmacokinetic parameters of oral tamoxifen, they induced increased trends of plasma tamoxifen concentrations, especially significant (p<0.05) increases of plasma tamoxifen concentrations were demonstrated at 0.5 hr after end of co-administration with GMSYS as compared with tamoxifen single formula treated rats, at dosage levels of tamoxifen 10 mg/kg and GMSYS 100 mg/kg within 5 min. It is considered that pharmacokinetic studies should be tested like the effects of GMSYS on the pharmacokinetics of tamoxifen, when they were co-administered with prolonger intervals than Tmax of tamoxifen oral administration (about 2.5 hr-intervals), to achieve the optimal dosing regimen of GMSYS and tamoxifen co-administration.

Keywords

References

  1. The BIG 1-98 Collaborative Group, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med, 2009;361(8):766-76. https://doi.org/10.1056/NEJMoa0810818
  2. Jordan VC, Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol, 2006;147 Suppl 1:S269-76. https://doi.org/10.1038/sj.bjp.0706399
  3. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG, Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med, 2006;144(2):101-6. https://doi.org/10.7326/0003-4819-144-2-200601170-00007
  4. Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, et al., Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol, 2007;52(1):106-14. https://doi.org/10.1016/j.eururo.2007.01.031
  5. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al., Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature, 2008;456(7222):663-6. https://doi.org/10.1038/nature07483
  6. Vehmanen L, Elomaa I, Blomqvist C, Saarto T, Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol, 2006;24(4):675-80. https://doi.org/10.1200/JCO.2005.02.3515
  7. Grilli S, Tamoxifen (TAM): the dispute goes on. Ann Ist Super Sanita, 2006;42(2):170-3.
  8. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, et al., Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation, 2005;111(5):650-6. https://doi.org/10.1161/01.CIR.0000154545.84124.AC
  9. Osman KA, Osman MM, Ahmed MH, Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf, 2007;6(1):1-4. https://doi.org/10.1517/14740338.6.1.1
  10. Paganini-Hill A, Clark LJ, Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat, 2000;64(2):165-76. https://doi.org/10.1023/A:1006426132338
  11. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ, Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage, 2004;21(1):364-71. https://doi.org/10.1016/j.neuroimage.2003.08.037
  12. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, et al., Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat, 2006;100(3):273-84. https://doi.org/10.1007/s10549-006-9260-6
  13. Karimian E, Chagin AS, Gjerde J, Heino T, Lien EA, Ohlsson C, et al., Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. J Bone Miner Res, 2008;23(8):1267-77. https://doi.org/10.1359/jbmr.080319
  14. Nalbandian G, Paharkova-Vatchkova V, Mao A, Nale S, Kovats S, The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol, 2005;175(4):2666-75. https://doi.org/10.4049/jimmunol.175.4.2666
  15. Rousset-Jablonski C, Thalabard JC, Gompel A, Tamoxifen contraindicated in women with hereditary angioedema? Ann Oncol, 2009;20(7):1281-2. https://doi.org/10.1093/annonc/mdp295
  16. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al., Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 1998;90(18):1371-88. https://doi.org/10.1093/jnci/90.18.1371
  17. Pienta KJ, Redman BG, Esper PS, Flaherty LE, A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate. Am J Clin Oncol, 1996;19(5):500-3. https://doi.org/10.1097/00000421-199610000-00014
  18. Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R, Use of tamoxifen before and during pregnancy. Oncologist, 2011;16(11):1547-51. https://doi.org/10.1634/theoncologist.2011-0121
  19. Terauchi M, Hiramitsu S, Akiyoshi M, Owa Y, Kato K, Obayashi S, et al., Effects of three Kampo formulae: Tokishakuyakusan (TJ-23), Kamishoyosan (TJ-24), and Keishibukuryogan (TJ-25) on Japanese peri- and postmenopausal women with sleep disturbances. Arch Gynecol Obstet, 2011;284(4):913-21. https://doi.org/10.1007/s00404-010-1779-4
  20. Hidaka T, Yonezawa R, Saito S, Kami-shoyo-san, Kampo (Japanese traditional medicine), is effective for climacteric syndrome, especially in hormone-replacement-therapy-resistant patients who strongly complain of psychological symptoms. J Obstet Gynaecol Res, 2013;39(1):223-8. https://doi.org/10.1111/j.1447-0756.2012.01936.x
  21. Kimura Y, Takamatsu K, Fujii A, Suzuki M, Chikada N, Tanada R, et al., Kampo therapy for premenstrual syndrome: efficacy of Kamishoyosan quantified using the second derivative of the fingertip photoplethysmogram. J Obstet Gynaecol Res, 2007;33(3):325-32. https://doi.org/10.1111/j.1447-0756.2007.00531.x
  22. Qu Y, Gan HQ, Mei QB, Liu L, Study on the effect of Jia-Wei-Xiao-Yao-San decoction on patients with functional dyspepsia. Phytother Res, 2010;24(2):245-8. https://doi.org/10.1002/ptr.2920
  23. Ishikawa T, Funahashi T, Kudo J, Effectiveness of the Kampo kami-shoyo-san (TJ-24) for tremor of antipsychotic-induced parkinsonism. Psychiatry Clin Neurosci, 2000;54(5):579-82. https://doi.org/10.1046/j.1440-1819.2000.00756.x
  24. Jung MY, Seo CS, Baek SE, Lee J, Shin MS, Kang KS, et al., Analysis and Identification of Active Compounds from Gami-Soyosan Toxic to MCF-7 Human Breast Adenocarcinoma Cells. Biomolecules, 2019;9(7).
  25. Bailer AJ, Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm, 1988;16(3):303-9. https://doi.org/10.1007/BF01062139
  26. Chiou WL, Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. J Pharmacokinet Biopharm, 1978;6(6):539-46. https://doi.org/10.1007/BF01062108
  27. Adam HK, Patterson JS, Kemp JV, Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep, 1980;64(6-7):761-4.
  28. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F, Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem, 1987;26(5):547-55. https://doi.org/10.1016/0022-4731(87)90006-9
  29. Jordan VC, Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat, 1982;2(2):123-38. https://doi.org/10.1007/BF01806449
  30. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, et al., Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos, 2007;35(11):2006-14. https://doi.org/10.1124/dmd.107.017145
  31. Hall WA, Doolittle ND, Daman M, Bruns PK, Muldoon L, Fortin D, et al., Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol, 2006;77(3):279-84. https://doi.org/10.1007/s11060-005-9038-4
  32. Notley LM, Crewe KH, Taylor PJ, Lennard MS, Gillam EM, Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its a-hydroxy and a,4-dihydroxy derivatives. Chem Res Toxicol, 2005;18(10):1611-8. https://doi.org/10.1021/tx050140s
  33. Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM, Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res, 1990;50(18):5851-7.
  34. Tenni P, Lalich DL, Byrne MJ, Life threatening interaction between tamoxifen and warfarin. BMJ, 1989;298(6666):93. https://doi.org/10.1136/bmj.298.6666.93
  35. Lamberts SW, Verleun T, Hofland L, Oosterom R, Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab, 1986;63(6):1342-7. https://doi.org/10.1210/jcem-63-6-1342
  36. Dowsett M, Pfister C, Johnston SR, Miles DW, Houston SJ, Verbeek JA, et al., Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res, 1999;5(9):2338-43.
  37. Reid AD, Horobin JM, Newman EL, Preece PE, Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients. Breast Cancer Res Treat, 1992;22(2):153-6. https://doi.org/10.1007/bf01833345
  38. Dehal SS, Brodie AM, Kupfer D, The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy. Drug Metab Dispos, 1999;27(3):389-94.
  39. West CM, Reeves SJ, Brough W, Additive interaction between tamoxifen and rifampicin in human biliary tract carcinoma cells. Cancer Lett, 1990;55(2):159-63. https://doi.org/10.1016/0304-3835(90)90027-U
  40. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al., Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos, 2002;30(8):883-91. https://doi.org/10.1124/dmd.30.8.883
  41. Kwak MA, Park SJ, Park SH, Lee YJ, Ku SK, Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (1) - Single Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg within 5 min -. J Korean Med, 2016;37(2):1-11. https://doi.org/10.13048/jkm.16016
  42. Park SJ, Kwak MA, Park SH, Lee YJ, Ku SK, Effect of Jaeumkanghwatang (JEKHT), a Polyherbal Formula on the Pharmacokinetics Profiles of Tamoxifen in Male SD Rats (2) - Oral Combination Treatment of Tamoxifen 50 mg/kg with JEKHT 100 mg/kg on JEKHT 6-day Repeated Pretreated Rats with 8-day Repeated. J Soc Prev Korean Med, 2016;20(2):97-109.

Cited by

  1. Effect of 2.5 hr-interval single oral combination treatment of Gamisoyo-san with Tamoxifen on the pharmacokinetics profiles of Tamoxifen in rats vol.41, pp.4, 2020, https://doi.org/10.13048/jkm.20039